Patients with moderate or severe atopic dermatitis (AD) had as much as 74% improvement in disease status with the oral Janus kinase (JAK) inhibitor upadacitinib, a randomized trial showed.
Even though 15 times more petroleum is consumed as fuel than is used as ingredients in industrial and consumer products, the amount of chemical vapors emitted to the atmosphere in scented products is roughly the same, said lead author Brian McDonald, a CIRESoffsite link scientist working at NOAA.
The chemical vapors, known as volatile organic compounds or VOCs, react with sunlight to form ozone pollution, and, as this study finds, also react with other chemicals in the atmosphere to form fine particulates in the air.
Late last week, Congress passed and the President signed a sweeping spending bill that will fund the government through March 23 and raise the spending caps imposed by the Budget Control Act of 2011 for two years, paving the way for a longer-term spending agreement. The legislation – the Bipartisan Budget Act of 2018 (BBA of 2018) – also contains a number of health care provisions important to people with Medicare and their families, including changes to Medicare Part D prescription drug coverage that will close the donut hole in 2019.
Just days later, on February 12, the White House released President Trump’s fiscal year (FY) 2019 budget request to Congress, which also includes several proposals related to Medicare, including changes to Part D drug coverage and Part B drug reimbursement.
The BBA of 2018 also addressed critical “extenders” – creating permanent fixes for the therapy cap and extending for two years funding for critical Medicare outreach and assistance activities. But the bill also included increases in premiums for some higher-income beneficiaries, further means testing the program. Both the legislation and the budget request allow for more flexibility for private Medicare Advantage plans and target Medicare Part D for a number of changes.
Decades ago, before “aging in place” became a movement, a small group of residents in rural Leelanau County began a conversation.
That led to a plan: a grassroots network of volunteers and basic services for the elderly so they could remain in their homes as long as possible.
More than 20 years later, Pauline McClure, 91, is still in her home in Northport, a pretty beachfront town popular with retirees north of Traverse City. That’s in no small part due to ShareCare of Leelanau Inc., the nonprofit that grew from those discussions.
“It’s almost a lifesaver,” McClure said.
McClure was a ShareCare charter member in 1994. She’s served on its board, as board vice president and has given her time driving members to dental or medical appointments, visiting the lonely or taking meals to those in need.
Now she’s on the receiving end.
“When we were younger, we said, ‘We’ll never need that.’ Well, now I’m the one having to ask for help once in a while,” McClure said.
There’s another name for what ShareCare does ‒ what’s become known nationally as the “village movement” that now counts 230 like-minded programs across the United States, with another 130 in development. Officially the Village to Village Network, it traces its origins to a Boston nonprofit called Beacon Hill Village that opened in 2002 – eight years after network member ShareCare was founded on similar principles.
As explained in a report from the Daily Mail, a team of researchers from the University of Oregon examined a total of 117 mammoth prints dating back to approximately 43,000 years ago, with these fossilized footprints first spotted in 2014, and excavated some time later. In 2017, the Oregon Bureau of Land Management gave study lead author and University of Oregon professor Greg Retallack and his colleagues permission to return to the area. This was when the researchers’ interest was piqued by a collection of about 20 Ice Age mammoth footprints that hinted at some interesting behavior from the prehistoric elephants.
After analyzing the footprints, the researchers concluded that they might have belonged to Columbian mammoths that were, during those times, quite plentiful in certain parts of the present-day United States. A look at the 20 recently spotted footprints suggested that some of the prints came from a wounded, possibly elderly mammoth, with the other prints coming from younger mammoths.
The researchers found that by keeping KYNA levels low throughout the worm’s life, they could prevent the onset of age-related decline – the worms kept learning. In older worms already impaired, lowering KYNA levels could counteract the impairments – raising hope that interventions later in life may be effective in reversing neurological decline.
The reason that KYNA increases with age is still a mystery, but the new study offers an intriguing hint, by linking KYNA buildup in aging worms to elevated levels of insulin, a hormone that controls blood sugar in both worms and humans. In contrast, earlier experiments by Ashrafi’s team had found that fasting, which has been linked to longevity, reduced levels of KYNA in worms and improved learning and memory.
Disability Competent Care Resources
- ACC DCC Assessment Tool
- 5 Questions to Ask Yourself
- 10 Simple Steps to Disability Competent Care
- Communication Access Best Practices
- Programmatic Access Best Practices
- Physical Access Best Practices
- Tax Incentives
- DCC Feedback
New data showed that nearly 15% of adult ibuprofen users exceeded the maximum recommended dose of ibuprofen or other NSAIDs in a 1-week period.
An online study analyzed nonsteroidal anti-inflammatory drugs (NSAID) use with a 1-week diary study in included 1,326 ibuprofen users. The vast majority (90%) of ibuprofen use was with over-the-counter (OTC) agents.
Of the participants, 37% took non-ibuprofen NSAID; the rest took ibuprofen. Those that exceeded the recommended daily NSAID limits included 11% on ibuprofen and 4% on other NSAIDs. This occurred an average of 9.1% of NSAID usage days.
Those with excessive daily use were more likely to be male, with ongoing pain, poor physical function, daily smoking, and the attitude of "choosing my own dose" and not starting with the lowest dose. They also had poor knowledge of the recommended one-time and 24-hour dose limits.
Among the 611 counties in this study, Medicaid expansion was associated with an increase in overall cancer diagnoses of 13.8 per 100 000 population (95% confidence interval [CI] = 0.7, 26.9), or 3.4%. Medicaid expansion was also associated with an increase in early-stage diagnoses of 15.4 per 100 000 population (95% CI = 5.4, 25.3), or 6.4%. There was no detectable impact on late-stage diagnoses.
Conclusions. In their first year, the 2014 Medicaid expansions were associated with an increase in cancer diagnosis, particularly at the early stage, in the working-age population.
A new study, however, focused on the effect of nicotinamide riboside (NR), which is a form of vitamin B-3, on Alzheimer's-related brain damage in mice.
More specifically, the researchers — who were jointly led by Dr. Vilhelm A. Bohr, the chief of the National Institute on Aging's (NIA) Laboratory of Molecular Gerontology, and Dr. Yujun Hou, a postdoctoral investigator in the laboratory — focused on how NR affects the brain's ability to repair its DNA, a function that is compromised in Alzheimer's disease.
As the scientists explain, a deficiency in the brain's ability to repair its DNA leads to dysfunction in the cells' mitochondria — the energy-creating organelles inside the cells — which, in turn, leads to neuronal dysfunction and lower neuron production.
But NR is "critical for mitochondrial health and biogenesis, stem cell self-renewal, and neuronal stress resistance." Thus, Dr. Bohr and his colleagues wanted to explore the effects of NR supplementation in a mouse model of the neurological disease.
Compared with the controls, the NR-treated mice had less of the protein tau in the brain, less DNA damage, and more neuroplasticity — that is, the brain's ability to "rewire" itself when it learns new things, stores new memories, or becomes damaged.
Also, fewer neurons died or were damaged in these mice. Intriguingly, however, their levels of the beta-amyloid protein stayed the same as those of the control mice.
Finally, the researchers say that in the hippocampi — a brain area involved in memory that often shrinks or is damaged in Alzheimer's — of the mice that received the treatment, NR appeared to get rid of the existing DNA damage or stop it from spreading.